Preliminary Final Report

Key points

• Income from ordinary activities increased by 214.6% to $559,080
• Loss from ordinary activities after tax increased by 151.1% to $(9,843,987)
• No dividends paid, recommended, or declared during the financial period
• Audit opinion issued was unmodified

Full summary

Island Pharmaceuticals Ltd released its preliminary final report for the year ended 30 June 2026, showing an increase in income from ordinary activities by 214.6% to $559,080. However, the loss from ordinary activities after tax increased by 151.1% to $(9,843,987). The company did not pay, recommend, or declare any dividends during the financial period. The financial statements were audited and received an unmodified opinion.

Guidance

Income from ordinary activities: $559,080; Loss after tax: $(9,843,987) for the year ended 30 June 2026